Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Urination × Genitourinary × Clear all

Status

Sponsor Class

OTHER 6 OTHER_GOV 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Genitourinary 1 Gastrointestinal 1

Conditions

Prostatic Neoplasms 1 Prostatic Hyperplasia 1

Interventions

acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 3 Zoledronic Acid 3 Saline Solution 3 enzalutamide 2 Radiosurgery 2 Magnetic Resonance Spectroscopy 2 Magnetic Resonance Imaging 2 LHRH, Ac-Nal(1)-Cpa(2)-Trp(3)-Arg(6)-Ala(10)- 2 Gemcitabine 2 Androgen Antagonists 2 Abiraterone Acetate 2 veliparib 1 darolutamide 1 bemarituzumab 1 avelumab 1 apatorsen 1 apalutamide 1 anlotinib 1 aldesleukin 1 abiraterone 1 Watchful Waiting 1 Urination 1 Transurethral Resection of Prostate 1 Tacrolimus 1 Surveys and Questionnaires 1 Surgical Procedures, Operative 1 Sunitinib 1 Standard of Care 1 Sirolimus 1 Single Photon Emission Computed Tomography Computed Tomography 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06116851 2023-11-03

PROMIC

Turku University Hospital

Prostatic Hyperplasia, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡